

Cover Story
More than a decade ago, Glenn Begley and Lee Ellis published a paper with astounding findings: of 53 “landmark” studies, only six, or 11%, were reproducible, even with the same reagents and the same protocols—and even, sometimes, in the same laboratory—as the original study.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for February 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Protecting the cure: Why the future of radiation oncology must be precision-guided
- Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research - Chernobyl: a 35 year follow up on long-term health effects
- Cancer AI Alliance announces first wave of pilot projects
















